Gland Pharma Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Srinivas Sadu

Chief Executive Officer (CEO)

₹123.6m

Compensación total

Porcentaje del salario del CEO	49.2%
Permanencia del CEO	5yrs
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Mar 19

Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Feb 16

Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

May 20

Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 07

Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers

Jul 22

Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?

Jul 14

Gland Pharma Limited (NSE:GLAND) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

May 19

Gland Pharma Limited's (NSE:GLAND) 27% Price Boost Is Out Of Tune With Earnings

Mar 04

Gland Pharma Limited's (NSE:GLAND) Stock Is Going Strong: Is the Market Following Fundamentals?

Feb 20

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Srinivas Sadu en comparación con los beneficios de Gland Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	₹7b
Sep 30 2023	n/a	n/a	₹7b
Jun 30 2023	n/a	n/a	₹7b
Mar 31 2023	₹124m	₹61m	₹8b
Dec 31 2022	n/a	n/a	₹10b
Sep 30 2022	n/a	n/a	₹10b
Jun 30 2022	n/a	n/a	₹11b
Mar 31 2022	₹124m	₹61m	₹12b
Dec 31 2021	n/a	n/a	₹12b
Sep 30 2021	n/a	n/a	₹11b
Jun 30 2021	n/a	n/a	₹10b
Mar 31 2021	₹89m	₹31m	₹10b
Dec 31 2020	n/a	n/a	₹9b
Jun 30 2020	n/a	n/a	₹9b
Mar 31 2020	₹59m	₹32m	₹8b
Mar 31 2019	₹23m	n/a	₹5b
Mar 31 2018	₹11m	₹5m	₹3b

Compensación vs. Mercado: La compensación total de Srinivas($USD1.48M) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD539.67K).

Compensación vs. Ingresos: La compensación de Srinivas ha sido consistente con los resultados de la empresa en el último año.

CEO

Srinivas Sadu (54 yo)

5yrs

Permanencia

₹123,580,000

Compensación

Mr. Srinivas Sadu, B. Pharm, M. S., MBA, PG Certificate in Finance and Management, has been Managing Director and Chief Executive Officer at Gland Pharma Ltd. since April 25, 2019 and serves as its Executi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Srinivas Sadu	MD, CEO & Executive Director	5yrs	₹123.58m	sin datos
Ravi Mitra	Chief Financial Officer	4.6yrs	₹15.15m	sin datos
Sampath Pallerlamudi	Company Secretary & Compliance Officer	no data	₹5.11m	sin datos
Prakash Baliga	Chief Operating Officer	less than a year	sin datos	0.000010% ₹ 28.5k
Ankit Gupta	Vice President of Strategy & Investments	less than a year	sin datos	sin datos
Sumanta Bajpayee	Vice President of Investor Relations	no data	sin datos	sin datos
Surinder Koul	Head of Domestic Marketing	less than a year	sin datos	sin datos
Shilpi Sahay	Deputy General Manager of Human Resources	no data	sin datos	sin datos
C. Venkatesan	Senior Vice President of R&D	no data	₹11.35m	0.0030% ₹ 8.7m
Surapanini Sridevi	Senior Vice President of R&D	no data	sin datos	sin datos
K Rao	Head of Quality	less than a year	sin datos	0.0055% ₹ 15.5m
Rong Wu	Chief Financial Controller	no data	sin datos	sin datos

0.6yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GLAND no se considera experimentado ( 0.6 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Srinivas Sadu	MD, CEO & Executive Director	5yrs	₹123.58m	sin datos
Fang Yao	Non-Executive & Non- Independent Director	2.1yrs	sin datos	sin datos
Naina Lal Kidwai	Independent Director	2.9yrs	₹10.40m	sin datos
Udo Vetter	Independent Director	6.2yrs	₹2.90m	sin datos
Jia Ai Zhang	Non-Independent Non Executive Director	2.9yrs	sin datos	sin datos
Yiu Kwan Lau	Independent Chairman	4.8yrs	₹4.97m	sin datos
Satyanarayana Chavali	Independent Director	5.4yrs	₹3.00m	sin datos
Chen Qiyu	Non-Executive & Non-Independent Director	6.5yrs	sin datos	sin datos
Essaji Vahanvati	Independent Director	3.6yrs	₹2.90m	sin datos

4.8yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de GLAND se considera experimentada (4.8 años de antigüedad promedio).

Gland Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Chief Technical Officer recently sold ₹14m worth of stock

Chief Operating Officer recently sold ₹2.8m worth of stock

Chief Technical Officer recently sold ₹27m worth of stock

Chief Technical Officer recently sold ₹27m worth of stock

Chief Technical Officer recently sold ₹10m worth of stock

Gland Pharma Limited Appoints Ankit Gupta as Vice-President (Strategy & Investments)

Recent updates

Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals

Chief Technical Officer recently sold ₹14m worth of stock

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Chief Operating Officer recently sold ₹2.8m worth of stock

Consensus EPS estimates fall by 11%, revenue upgraded

Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024

Chief Technical Officer recently sold ₹27m worth of stock

Chief Technical Officer recently sold ₹27m worth of stock

New minor risk - Insider selling

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q2, 2024 Results on Nov 06, 2023

Chief Technical Officer recently sold ₹10m worth of stock

Gland Pharma Limited Appoints Ankit Gupta as Vice-President (Strategy & Investments)

Investor sentiment improves as stock rises 23%

Gland Pharma Limited Appoints Prakash Vithal Baliga as Chief Operating Officer

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Gland Pharma Limited to Report Q1, 2024 Results on Aug 07, 2023

Investor sentiment deteriorates as stock falls 31%

Price target decreased by 12% to ₹1,520

Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

Gland Pharma Limited, Annual General Meeting, Aug 31, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insider recently sold ₹1.3m worth of stock

Insider recently sold ₹683k worth of stock

Investor sentiment improves as stock rises 16%

Insider recently sold ₹756k worth of stock

Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Price target decreased by 13% to ₹2,119

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Gland Pharma Limited to Report Q3, 2023 Results on Jan 23, 2023

Insider recently sold ₹798k worth of stock

Insider recently sold ₹869k worth of stock

Fosun Reportedly Planning Sale of Gland Pharma

China's Fosun Reportedly Said to Mull Sale of India's $3.6 Billion Gland Pharma

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q2, 2023 Results on Oct 26, 2022

Insider recently sold ₹4.1m worth of stock

Insider recently sold ₹2.3m worth of stock

Gland Pharma Limited Announces Xiaohui Guan and Yifang Wu Not Offer for Reappointment as Directors

Insider recently sold ₹1.6m worth of stock

Insider recently sold ₹1.4m worth of stock

Insider recently sold ₹2.3m worth of stock

Consensus revenue estimates fall by 16%

Price target decreased to ₹3,033

Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?

Gland Pharma Limited to Report Q1, 2023 Results on Jul 20, 2022

Insider recently sold ₹7.1m worth of stock

Insider recently sold ₹17m worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Gland Pharma Limited, Annual General Meeting, Aug 30, 2022

High number of new directors

Gland Pharma Limited to Report Q4, 2022 Results on May 19, 2022

Senior Vice President of R&D recently sold ₹19m worth of stock

Insider recently sold ₹660k worth of stock

Insider recently sold ₹1.7m worth of stock

Gland Pharma Limited Submits an Abbreviated New Drug Application to the U.S. Food and Drug Administration Seeking Approval to Manufacture, Use or Sell A Generic Version of GIAPREZA (Angiotensin II) in the U.S

Is Now The Time To Put Gland Pharma (NSE:GLAND) On Your Watchlist?

Third quarter 2022 earnings: EPS misses analyst expectations

Insider recently sold ₹7.1m worth of stock

Insider recently sold ₹368k worth of stock

Second quarter 2022 earnings released: EPS ₹18.37 (vs ₹20.24 in 2Q 2021)

Insider recently sold ₹6.0m worth of stock

Vice President of Operations recently sold ₹7.0m worth of stock

Insider recently sold ₹9.3m worth of stock